In a world where biotechnological innovation advances at an unprecedented pace, allocating a part of the portfolio to emerging companies with disruptive potential can be A strategic play for those investors with long -term vision. As happened with the digital revolution, the biotechnology applied to longevity is laying the foundations for what could be the next great transformation into science and health.
Aging, historically seen as an irreversible process, is now the center of one of the most promising areas of biotechnology. From cell reprogramming to senolitic drugs that eliminate aging cellscompanies that lead this field seek not only to prolong life expectancy, but to improve the quality of those additional years. The objective is ambitious: treating aging as a disease in itself and developing therapies that allow delay or even reverse it.
The sector has attracted millionaire investments and the support of names such as Jeff Bezos and Sam Altman, which reflects the growing conviction that extended longevity is an attainable challenge. In 2022, Altman invested in Retro Biosciences, a company that seeks to extend human life in 10 years. Bezos, meanwhile, has opted for high labs, a Startup dedicated to cell reprogramming. This growing interest has promoted a wave of scientific advances in gene therapy, stem cells and regenerative biotechnology.
Although still in initial stages, some companies already quote on the stock market and are taking their research to clinical trials with potential to revolutionize medicine. The investment in this sector is not exempt from risks, since many of these companies have not yet generated benefits or marketed their treatments. However, for a portfolio with a 20 -year -old horizon, it represents one of those long -term opportunities with high revaluation potential. Next, I will analyze some of the most innovative companies in the search for eternal youth, those that, although still in the development phase, could transform the way we age and open new borders in biomedicine.
Unity Biotechnology (Nasdaq: UBX)
Unity Biotechnology It is one of the pioneers in the development of senolithic therapies, which aim to eliminate senescent cells responsible for chronic inflammation and the deterioration of the organism with age. Initially, the company opted for diseases such as osteoarthritis and pulmonary fibrosis, although after some failed clinical trials, it has redirected its efforts towards ophthalmological diseases related to aging, such as macular degeneration and diabetic retinopathy. Currently, its UBX1325 drug is found in advanced clinical trials and could represent a significant advance in the treatment of degenerative views of the sight.
Technically, the most interesting thing is that the title established a probable long -term floor in the minimums that marked in October 2022 in the $ 0.31. The good news is that we can already identify another floor in the 0.93 dollars, which are the minimums that stopped the last correction of the title Last January. From them he has formed a rebound that has visions that he will try to look for new maximums on which he marked in 2023 around 6 dollars, on which the road would be clear towards the highs of 2020 and 2021 in the 10 and 15, 50 dollars.
Longeveron (Nasdaq: LGVN)
Longeveron It focuses on regenerative cellular therapies to treat fragility in older adults and other diseases associated with aging. Its main asset, Lomecel-B, is a therapy based on stem cells derived from bone marrow, designed to improve cardiovascular function and reduce inflammation. The company has shown promising results In their phase II clinical trials, with improvements in mobility and the general health of patients. In addition, Longeveron investigates the potential of its technology to treat rare diseases, such as hypoplastic left heart syndrome in babies, which expands its field of application beyond longevity.
From the technical point of view, it is very likely that Longeveron has established a soil of the bearish trend that began in its historical highs of the year 2021 in the $ 45 in the minimum of the year 2024 at $ 0.33. In fact, if everything goes well I shouldn’t lose or 0.78 dollarswhich are the minimum of June last year. At the moment it quotes around 2 dollars and it seems to me a very interesting option to diversify in the sector in search of the fact that at any time develop a new bullish impulse that should try to mark new maximums over those of last year in the 6 , 30 dollars. Above them would not find resistance worth highlighting up to 10 and 17 dollars.
Therapeutics (Nasdaq: MCRB) beings
Therapeutics beings investigate the role of microbiome in longevity and healthy aging. Its therapy development platform is based on the administration of beneficial intestinal bacteria to restore microbiota and improve immune health. Its main candidate, Ser-109, has proven effective in the Treatment of recurrent infections By Clostridium difficile, one of the main causes of death in hospitals due to resistant bacterial infections. The company also explores applications of its technology in metabolic, autoimmune and neurodegenerative diseases, which opens the door to new strategies to improve health and longevity by controlling the microbiome.
Therapeutics beings It is the one that could say that it is developing a clearer bunder pattern in the long term, in the form of double floor in the 0.50 dollars, which would be confirmed if it exceeds resistance in the $ 1.55. Seeking to overcome this resistance beings would be another option to diversify in the sector with a long -term orientation.
Bioovie Inc. (Nasdaq: Bivi)
Bioovie It is focused on the development of therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson, two of the main medical challenges associated with aging. Its NE3107 experimental drug seeks to reduce chronic inflammation and oxidative stress, key factors in cognitive impairment. In preliminary studies, it has shown improvements in brain function and patient motor capacity. In addition, the company also investigates treatments for liver diseases associated with age, which expands its potential in the biotechnology market focused on longevity.
Technically, the title has established a floor in the $ 0.34, which are the minimum of 2024. If everything goes well and their studies do not fail, it should no longer lose that level.
These companies represent different approaches within the longevity sector, From the elimination of senescent cells until cell regeneration and microbiome modulation. Its success will depend on clinical advances, regulatory approval and the validation of its market technologies. Although investing in this sector involves inherent risks, it also opens the door to one of the most promising areas of modern biotechnology. The possibility of extending human life in a significant way is no longer only an idea of science fiction, but a field of study with specific applications that could redefine the future of medicine and health.
If I had to choose two within this sector for the portfolio of my twins, I would bet on Therapeutics and Longeveron beings.
#Biotechnology #longevity #companies #defy #aging
